ImmunityBio Inc. (NASDAQ: IBRX)’s stock price has gone decline by -4.44 in comparison to its previous close of 1.80, however, the company has experienced a 11.69% increase in its stock price over the last five trading days. PennyStocks reported 2023-09-15 that Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily shorted, meaning a high percentage of the shares are held by investors betting the price will decline, it can set up a volatile “short squeeze.
Is It Worth Investing in ImmunityBio Inc. (NASDAQ: IBRX) Right Now?
compared to its average ratio and a 36-month beta value of 1.37. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for ImmunityBio Inc. (IBRX) is $5.00, which is $2.78 above the current market price. The public float for IBRX is 128.79M, and currently, short sellers hold a 20.75% ratio of that float. The average trading volume of IBRX on September 18, 2023 was 2.67M shares.
IBRX’s Market Performance
The stock of ImmunityBio Inc. (IBRX) has seen a 11.69% increase in the past week, with a -6.52% drop in the past month, and a -37.23% fall in the past quarter. The volatility ratio for the week is 13.82%, and the volatility levels for the past 30 days are at 9.22% for IBRX. The simple moving average for the past 20 days is 7.52% for IBRX’s stock, with a -43.82% simple moving average for the past 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Neutral.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $4 based on the research report published on May 12, 2023 of the current year 2023.
IBRX Trading at -15.69% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.77% of loss for the given period.
Volatility was left at 9.22%, however, over the last 30 days, the volatility rate increased by 13.82%, as shares sank -5.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.95% lower at present.
During the last 5 trading sessions, IBRX rose by +11.36%, which changed the moving average for the period of 200-days by -67.21% in comparison to the 20-day moving average, which settled at $1.5950. In addition, ImmunityBio Inc. saw -66.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBRX starting from BLASZYK MICHAEL D, who purchase 71,915 shares at the price of $2.75 back on Jun 05. After this action, BLASZYK MICHAEL D now owns 71,915 shares of ImmunityBio Inc., valued at $198,023 using the latest closing price.
Brennan John Owen, the Director of ImmunityBio Inc., purchase 25,000 shares at $2.83 during a trade that took place back on Jun 02, which means that Brennan John Owen is holding 25,000 shares at $70,700 based on the most recent closing price.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -146090.42 for the present operating margin
- -9980.00 for the gross margin
The net margin for ImmunityBio Inc. stands at -173569.58. Equity return is now at value 92.60, with -140.30 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 2,431.40, with the company’s debt to enterprise value settled at 0.27. The receivables turnover for the company is 0.15 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.28.
Conclusion
To put it simply, ImmunityBio Inc. (IBRX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
